Summary
26.33 0.18(0.69%)10/04/2024
Evolent Health Inc (EVH)
Evolent Health Inc (EVH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.69 | -10.14 | -12.29 | 31.65 | -11.85 | 0.57 | 253.42 | 39.61 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 26.33 | |
| Open | 26.25 | |
| High | 27.28 | |
| Low | 26.00 | |
| Volume | 1,346,867 | |
| Change | 0.18 | |
| Change % | 0.69 | |
| Avg Volume (20 Days) | 1,646,090 | |
| Volume/Avg Volume (20 Days) Ratio | 0.82 | |
| 52 Week Range | 17.98 - 34.99 | |
| Price vs 52 Week High | -24.75% | |
| Price vs 52 Week Low | 46.44% | |
| Range | 0.30 | |
| Gap Up/Down | -0.49 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,365 | |
| EBIDTA | 123,438,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -1.3700 | |
| WallStreet Target Price | 42.62 | |
| Book Value | 9.1400 | |
| Earnings Per Share | -1.2600 | |
| EPS Estimate Current Quarter | 0.2700 | |
| EPS Estimate Next Quarter | 0.2600 | |
| EPS Estimate Current Year | 1.3000 | |
| EPS Estimate Next Year | 1.6900 | |
| Diluted EPS (TTM) | -1.2600 | |
| Revenues | ||
| Profit Marging | -0.0507 | |
| Operating Marging (TTM) | 0.0091 | |
| Return on asset (TTM) | 0.0062 | |
| Return on equity (TTM) | -0.0875 | |
| Revenue TTM | 2,175,858,944 | |
| Revenue per share TTM | 19.2830 | |
| Quarterly Revenue Growth (YOY) | 0.4960 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 316,584,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 21.7391 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.2140 | |
| Revenue Enterprise Value | 1.9775 | |
| EBITDA Enterprise Value | -156.6896 | |
| Shares | ||
| Shares Outstanding | 116,199,000 | |
| Shares Float | 110,953,173 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.11 | |
| Insider (%) | 3.97 | |
| Institutions (%) | 110.72 | |
10/02 12:08 EST - gurufocus.com
Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2
Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of $27.05.
Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2
Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of $27.05.
08/23 09:00 EST - seekingalpha.com
Evolent Health: Let The Bidding Begin
Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but potential bidding wars may drive up the stock price further. Evolent's current valuation at 21x forward free cash flow may undervalue the company, potentially leading to higher bids in the future.
Evolent Health: Let The Bidding Begin
Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but potential bidding wars may drive up the stock price further. Evolent's current valuation at 21x forward free cash flow may undervalue the company, potentially leading to higher bids in the future.
08/22 13:22 EST - reuters.com
Exclusive: Evolent Health in sale talks after inbound interest, sources say
Evolent Health is in talks with private equity firms and other companies for a potential sale, in a process that kicked off after the healthcare services provider received inbound interest, people familiar with the matter said on Thursday.
Exclusive: Evolent Health in sale talks after inbound interest, sources say
Evolent Health is in talks with private equity firms and other companies for a potential sale, in a process that kicked off after the healthcare services provider received inbound interest, people familiar with the matter said on Thursday.
08/09 10:30 EST - zacks.com
Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
08/08 21:18 EST - seekingalpha.com
Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript
08/08 18:31 EST - zacks.com
Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.14 per share a year ago.
Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.14 per share a year ago.
08/08 16:10 EST - prnewswire.com
Evolent Announces Second Quarter 2024 Results
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.
Evolent Announces Second Quarter 2024 Results
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.
08/04 06:46 EST - investorplace.com
3 Top Tech Stocks Ready for Robust Gains
Investors must always balance growth and stability in their portfolios. While employing defensive positions is essential, deploying capital in high-growth sectors like technology can be a formula that accelerates growth.
3 Top Tech Stocks Ready for Robust Gains
Investors must always balance growth and stability in their portfolios. While employing defensive positions is essential, deploying capital in high-growth sectors like technology can be a formula that accelerates growth.
07/17 08:45 EST - zacks.com
Evolent Health (EVH) Moves 12.8% Higher: Will This Strength Last?
Evolent Health (EVH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Evolent Health (EVH) Moves 12.8% Higher: Will This Strength Last?
Evolent Health (EVH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
07/11 08:00 EST - prnewswire.com
Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Company to Participate in Upcoming Conferences WASHINGTON , July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.
Evolent To Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Company to Participate in Upcoming Conferences WASHINGTON , July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com.
06/04 07:00 EST - prnewswire.com
Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify
Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics Acquisition expected to benefit health plans, clinicians, and members WASHINGTON , June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"), (NYSE: EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a proven software platform that leverages the latest advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applications and AI capabilities into its leading platform.
Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify
Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's specialty condition management platform through AI-enabled clinical workflow automation Machinify technology leverages the latest advances in applied machine learning, large language models and data analytics Acquisition expected to benefit health plans, clinicians, and members WASHINGTON , June 4, 2024 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company"), (NYSE: EVH) a company focused on achieving better health outcomes for people with complex conditions, today announced it has entered into an agreement to acquire certain assets of Machinify and the exclusive, perpetual and royalty-free license of Machinify Auth, a proven software platform that leverages the latest advances in artificial intelligence to increase the clinical quality, speed and consistency of the clinical reviews for all specialty conditions. Evolent plans to integrate the Machinify Auth team, software applications and AI capabilities into its leading platform.
05/10 10:30 EST - zacks.com
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/09 19:51 EST - zacks.com
Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago.
Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.21 per share a year ago.
05/09 16:15 EST - prnewswire.com
Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.
Digital cancer care platform Careology and Evolent (NYSE: EVH) to offer an innovative platform to enable cancer navigation Evolent will embed Careology's digital cancer care technology within its comprehensive care navigation services offered to health plan clients across the U.S. WASHINGTON , May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a $2 billion revenue company focused on achieving better health outcomes for people with complex conditions, today announced it is partnering with Careology , a digital cancer care platform, to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S. Evolent works with more than 70 health plans — spanning approximately 40 million unique members — to improve the quality and affordability of care for cancer and other conditions. The agreement will bring together Careology's "patient-first" digital solution with Evolent's comprehensive care navigation services.
Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.
Digital cancer care platform Careology and Evolent (NYSE: EVH) to offer an innovative platform to enable cancer navigation Evolent will embed Careology's digital cancer care technology within its comprehensive care navigation services offered to health plan clients across the U.S. WASHINGTON , May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a $2 billion revenue company focused on achieving better health outcomes for people with complex conditions, today announced it is partnering with Careology , a digital cancer care platform, to enable more coordinated, connected and empowered journeys for people living with cancer in the U.S. Evolent works with more than 70 health plans — spanning approximately 40 million unique members — to improve the quality and affordability of care for cancer and other conditions. The agreement will bring together Careology's "patient-first" digital solution with Evolent's comprehensive care navigation services.
05/09 16:10 EST - prnewswire.com
Evolent Announces First Quarter 2024 Results
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.
Evolent Announces First Quarter 2024 Results
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.
04/18 16:30 EST - prnewswire.com
Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Company to Participate in Upcoming Conferences WASHINGTON , April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com.
Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Company to Participate in Upcoming Conferences WASHINGTON , April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com.
03/14 10:56 EST - zacks.com
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
02/27 10:56 EST - zacks.com
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
The consensus price target hints at a 35.7% upside potential for Evolent Health (EVH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
02/22 22:34 EST - seekingalpha.com
Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q4 2023 Earnings Call Transcript
02/22 16:10 EST - prnewswire.com
Evolent Announces Fourth Quarter and Full Year 2023 Results
WASHINGTON , Feb. 22, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended December 31, 2023. Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year.
Evolent Announces Fourth Quarter and Full Year 2023 Results
WASHINGTON , Feb. 22, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended December 31, 2023. Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year.